Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Royal Bank of Canada
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Royal Bank of Canada
Royal Bank of Canada assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report published on Friday morning, The Fly reports. The firm issued an outperform rating and a $23.00 price objective on the biopharmaceutical company's stock.
加拿大皇家银行假设为以下股票提供保险 马里纳斯制药（纳斯达克股票代码：MRNS — 获取评级） 据The Fly报道，在周五早上发布的一份报告中。该公司对这家生物制药公司的股票发布了跑赢大盘的评级和23.00美元的目标股价。
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a report on Friday, January 6th. StockNews.com upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Monday, November 14th. Finally, Robert W. Baird lowered their target price on Marinus Pharmaceuticals from $32.00 to $24.00 and set an outperform rating on the stock in a report on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of Moderate Buy and a consensus price target of $28.13.
其他一些股票研究分析师最近也对该公司进行了权衡。HC Wainwright在1月6日星期五的一份报告中重申了买入评级，并对Marinus Pharmicals的股票发布了27.00美元的目标股价。StockNews.com在11月14日星期一的一份报告中将Marinus Pharmicals的评级从卖出上调至持有。最后，罗伯特·贝尔德将Marinus Pharmicals的目标价格从32.00美元下调至24.00美元，并在11月9日星期三的一份报告中对该股设定了跑赢大盘的评级。一位投资分析师对该股进行了持有评级，七位对该股给出了买入评级。根据Marketbeat.com的数据，Marinus Pharmicals目前的平均评级为适度买入，共识目标价为28.13美元。
Marinus Pharmaceuticals Stock Performance
马里纳斯制药股票表现
MRNS opened at $5.65 on Friday. The stock has a market cap of $210.16 million, a P/E ratio of -12.28 and a beta of 1.10. The company has a debt-to-equity ratio of 0.91, a current ratio of 8.41 and a quick ratio of 8.40. The stock's 50 day simple moving average is $4.42 and its 200 day simple moving average is $5.46. Marinus Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $12.37.
周五，MRNS开盘价为5.65美元。该股的市值为2.1016亿美元，市盈率为-12.28，beta值为1.10。该公司的债务与权益比率为0.91，流动比率为8.41，速动比率为8.40。该股的50天简单移动平均线为4.42美元，其200天简单移动平均线为5.46美元。Marinus Pharmicals创下1年低点3.46美元，1年高点为12.37美元。
Institutional Inflows and Outflows
机构流入和流出
A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,691,370 shares of the biopharmaceutical company's stock worth $11,248,000 after purchasing an additional 16,812 shares during the period. BlackRock Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.9% during the 3rd quarter. BlackRock Inc. now owns 959,198 shares of the biopharmaceutical company's stock worth $6,379,000 after purchasing an additional 17,887 shares during the period. Delphia USA Inc. purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth $86,000. Renaissance Technologies LLC lifted its stake in shares of Marinus Pharmaceuticals by 23.2% during the 3rd quarter. Renaissance Technologies LLC now owns 193,325 shares of the biopharmaceutical company's stock worth $1,286,000 after purchasing an additional 36,425 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Marinus Pharmaceuticals by 392.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 527,925 shares of the biopharmaceutical company's stock worth $3,511,000 after purchasing an additional 420,802 shares during the period. Hedge funds and other institutional investors own 86.88% of the company's stock.
许多大型投资者最近改变了他们在业务中的立场。Vanguard Group Inc.在第三季度将其在Marinus Pharmicals的股份提高了1.0％。Vanguard Group Inc.在此期间又购买了16,812股股票后，现在拥有这家生物制药公司的1,691,370股股票，价值11,24.8万美元。贝莱德公司在第三季度将其在Marinus Pharmicals的股份上调了1.9％。贝莱德公司在此期间又购买了17,887股股票后，现在拥有这家生物制药公司959,198股股票，价值6,379,000美元。Delphia USA Inc.在第三季度购买了Marinus Pharmicals的新股票，价值8.6万美元。Renaissance Technologies LLC在第三季度将其在马里努斯制药的股份提高了23.2％。Renaissance Technologies LLC在此期间又购买了36,425股股票后，现在拥有这家生物制药公司的193,325股股票，价值128.6万美元。最后，Assenagon Asset Management S.A. 在第三季度将其在Marinus Pharmicals的股份上调了392.8％。Assenagon Asset Management S.A. 在此期间又购买了420,802股股票后，现在拥有这家生物制药公司的527,925股股票，价值351.1万美元。对冲基金和其他机构投资者拥有该公司86.88％的股票。
Marinus Pharmaceuticals Company Profile
马里纳斯制药公司简介
(Get Rating)
（获取评分）
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Marinus Pharmicals, Inc是一家制药公司，专注于为患有罕见遗传性癫痫和其他癫痫发作障碍的患者开发和商业化产品。它提供ZTALMY，一种口服混悬剂，用于治疗与细胞周期蛋白依赖性激酶样5缺乏症相关的癫痫发作，适用于急性和慢性护理以及住院和自我给药环境中的成人和儿科患者。
See Also
另见
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
- 免费获取 StockNews.com 关于 Marinus Pharmicals (MRNS) 的研究报告
- 诺斯罗普·格鲁曼公司的抛售是机会吗？
- 新首席执行官上任 Under Armor 股票的最差表现是否落后？
- 微软对ChatGBT的投资对MSFT股票意味着什么？
- 像 The Fit of Skechers USA
- 我们能相信标准普尔500指数的涨势吗
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收《马里努斯制药日报》的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Marinus Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。